NCT07093866 - Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer：a Phase II Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions

mCRPC

Interventions

DRUG

Disitamab Vedotin (RC48)

Disitamab Vedotin 2mg/kg is administered intravenously once every 2 weeks (1 cycle)

DRUG

Abiraterone + prednisone

Abiraterone 1000mg is administered orally once a day，and prednisone 5mg is administered orally twice a day.

Trial Locations (1)

RECRUITING

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210000, Nanjing

All Listed Sponsors

collaborator

Nanjing University

OTHER

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER